◆英語タイトル:Vericel Corp (VCEL) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1293
◆発行会社(調査会社):
GlobalData
◆発行日:2020年4月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Vericel Corp (VCEL) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Vericel Corp (Vericel) develops and markets advanced cell therapies for sports medicine and severe burn care domain. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts for skin replacement. It also holds an exclusive license for NexoBrid in North America for the treatment of severe thermal burns. It has cell manufacturing facility in. The company sells its products through clinical support specialists. Vericel is headquartered in Cambridge, Massachusetts, the US.
Vericel Corp Key Recent Developments
Apr 02,2020: Vericel provides business and financial updates
Feb 25,2020: Vericel reports fourth quarter and full-year 2019 financial results and provides full-year 2020 financial guidance
Nov 06,2019: Vericel announces appointment of Sean C. Flynn as Vice President and General Counsel
Nov 05,2019: Vericel reports record third quarter revenues, net income and operating cash flow
Aug 06,2019: Vericel reports second quarter 2019 financial results and raises full year 2019 Revenue Guidance
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Vericel Corp – Key Facts
Vericel Corp – Key Employees
Vericel Corp – Key Employee Biographies
Vericel Corp – Major Products and Services
Vericel Corp – History
Vericel Corp – Company Statement
Vericel Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Vericel Corp – Business Description
Product Category: Epicel
Overview
Performance
Product Category: MACI
Overview
Performance
R&D Overview
Vericel Corp – Corporate Strategy
Vericel Corp – SWOT Analysis
SWOT Analysis – Overview
Vericel Corp – Strengths
Vericel Corp – Weaknesses
Vericel Corp – Opportunities
Vericel Corp – Threats
Vericel Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Vericel Corp, Medical Equipment, Deals By Year, 2014 to YTD 2020
Vericel Corp, Medical Equipment, Deals By Type, 2014 to YTD 2020
Vericel Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 02, 2020: Vericel provides business and financial updates
Feb 25, 2020: Vericel reports fourth quarter and full-year 2019 financial results and provides full-year 2020 financial guidance
Nov 06, 2019: Vericel announces appointment of Sean C. Flynn as Vice President and General Counsel
Nov 05, 2019: Vericel reports record third quarter revenues, net income and operating cash flow
Aug 06, 2019: Vericel reports second quarter 2019 financial results and raises full year 2019 Revenue Guidance
May 07, 2019: Vericel reports first quarter 2019 financial results and raises full year 2019 revenue guidance
Feb 26, 2019: Vericel announces fourth quarter and full-year 2018 financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Vericel Corp, Key Facts
Vericel Corp, Key Employees
Vericel Corp, Key Employee Biographies
Vericel Corp, Major Products and Services
Vericel Corp, History
Vericel Corp, Other Locations
Vericel Corp, Subsidiaries
Vericel Corp, Key Competitors
Vericel Corp, Ratios based on current share price
Vericel Corp, Annual Ratios
Vericel Corp, Annual Ratios (Cont...1)
Vericel Corp, Interim Ratios
Vericel Corp, Medical Equipment, Deals By Year, 2014 to YTD 2020
Vericel Corp, Medical Equipment, Deals By Type, 2014 to YTD 2020
Vericel Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Vericel Corp, Performance Chart (2015 - 2019)
Vericel Corp, Ratio Charts
Vericel Corp, Medical Equipment, Deals By Year, 2014 to YTD 2020
Vericel Corp, Medical Equipment, Deals by Type, 2014 to YTD 2020